Table 2.
Population pharmacokinetic parameters of TREO following an intravenous infusion to HSCT pediatric patients
| First author | Ten Brink et al. [20] | Danielak et al. [23] | van der Stoep et al. [24]a | Chiesa et al. [21] |
|---|---|---|---|---|
| Patients [N (infants)] | 20 (no data) | 15 (1) | 77 (12) | 22 (6) |
| Age, years | 6.2 ± 5.4 (mean ± SD) | 7.8 ± 4.9 (mean ± SD) | Median 4.8 (IQR 0.6–11.4) | Median 1.5 (range 0.08–14) |
| Dose, g/m2 | 14 | 10, 12, or 14 | 10 or 14 | 10, 12, or 14 |
| Infusion time, h | 3 | 1 or 2 | 3 | 2 |
| Disposition model | One-compartment | Two-compartment | Two-compartment | Two-compartment |
| Vss, L/kg | 0.66 | 0.51 | 0.60 | 0.49 |
| Cltot, mL/min/kg (CV%) | 5.71 (13) | 3.50 (26) | 5.82 (38) | 3.00 (no data) |
Cltot total clearance, CV coefficient of variation, IQR interquartile range, SD, standard deviation, Vss volume of distribution at steady state, TREO treosulfan, HSCT hematopoietic stem cell transplantation
aExtended model developed on the basis of the model by ten Brink et al. [20]